Currently out of the existing stock ratings of Ashwani Verma, 28 are a BUY (68.29%), 10 are a HOLD (24.39%), 3 are a SELL (7.32%).

Ashwani Verma

Work Performance Price Targets & Ratings Chart

Analyst Ashwani Verma works at UBS with a stock forecast success ratio of 50.6% fulfilled within 121.21 days on average.

Ashwani Verma’s has documented 82 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on JAZZ, Jazz Pharmaceuticals PLC at 01-Mar-2024.

Wall Street Analyst Ashwani Verma

Analyst best performing recommendations are on TEVA (TEVA PHARMA INDUSTRIES LTD ADR).
The best stock recommendation documented was for ITCI (INTRACELLULAR TH) at 3/29/2023. The price target of $63 was fulfilled within 19 days with a profit of $6.01 (10.55%) receiving and performance score of 5.55.

Average potential price target upside

ITCI Intracellular Th HZNP Horizon Pharma PLC CHRS Coherus BioSciences JAZZ Jazz Pharmaceuticals PLC RPRX Royalty Pharma Plc TEVA Teva Pharma Industries Ltd ADR VTRS Viatris CYTK Cytokinetics KRTX Karuna Therapeutics NBIX Neurocrine Biosciences UTHR United Therapeutics ALKS Alkermes Plc AXSM Axsome Therapeutics RANI Rani Therapeutics Holdings

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

82

$14.3 (21.12%)

82

14 days ago

14/16 (87.5%)

$14.79 (22.01%)

161

Buy

101

$33.3 (49.19%)

101

1 months 27 days ago

14/23 (60.87%)

$30.84 (43.96%)

560

Buy

100

$32.3 (47.71%)

101

1 months 27 days ago

2/10 (20%)

$29.84 (42.53%)

606

Buy

86

$18.3 (27.03%)

86

1 months 27 days ago

12/18 (66.67%)

$15.84 (22.58%)

255

Buy

82

$14.3 (21.12%)

76

2 months 3 days ago

6/8 (75%)

$6.35 (8.39%)

307

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Ashwani Verma is most bullish on?

Potential upside of $38.89 has been obtained for AXSM (AXSOME THERAPEUTICS)

Which stock is Ashwani Verma is most reserved on?

Potential downside of -$13.19 has been obtained for CYTK (CYTOKINETICS)

What Year was the first public recommendation made by Ashwani Verma?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?